Highlights

  • The Hailie system combines connected inhaler sensors, mobile applications and data-sharing tools designed to help healthcare providers understand medicine-use patterns.
  • Adherium’s 2026 annual reporting identifies the Hailie ecosystem as including hardware, firmware, mobile applications, desktop connections and a cloud platform.
  • In September 2026, the company disclosed consolidation of funding into a A$4.67 million term loan.
  • Clinical or commercial results require evidence beyond technology descriptions.

Adherium is a digital health company developing connected respiratory-monitoring devices and software through its Hailie platform. In 2026, Adherium Limited (ASX:ADR) reported activity relating to its research, products or operating strategy.

Technology and Product Direction

The Hailie system combines connected inhaler sensors, mobile applications and data-sharing tools designed to help healthcare providers understand medicine-use patterns. The company identifies application programming interfaces and software development tools among its integration capabilities. The work described by Adherium Limited (ASX:ADR) should be assessed against the specific product or research programme involved.

Reported Developments During 2026

Adherium’s 2026 annual reporting identifies the Hailie ecosystem as including hardware, firmware, mobile applications, desktop connections and a cloud platform. Together, these components support remote collection and communication of inhaler-use information. These are the 2026 activities identified in disclosures by Adherium Limited (ASX:ADR).

How the Programme Works

In September 2026, the company disclosed consolidation of funding into a A$4.67 million term loan. Its investor updates also reported additional financing arrangements in August and October 2026, demonstrating that funding remains an important operating consideration. The distinction matters when considering how Adherium Limited (ASX:ADR) describes its technical objectives.

Development and Operating Considerations

Compatibility with clinical workflows matters because recorded inhaler events need to be accessible and interpretable by the people managing respiratory care. Technical interoperability alone does not establish deployment across any particular hospital network. For Adherium Limited (ASX:ADR), these remain relevant operating considerations.

Key Insights

Clinical integration requires attention to data governance, device compatibility, workflow adoption and sustained operating resources. The existence of integration tools should not be confused with evidence of universal connection to electronic health records.